Kereos, Inc
 
 

In The News

Ultra-tiny "bees" target tumors
(CNNHealth.com 8/18/2009)
read more

Nano-sized technology has super-sized effect on tumors
(Washington University release 4/2/2008)
read more

Publications

Kereos’ collaborators have published dozens of research papers on the discovery of Kereos’ targeted therapy and molecular imaging candidates.
A few of note:

Cancer MRI
Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, Zhang H, Robertson DJ, Wickline SA, Lanza GM: Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel avb3-targeted nanoparticle and 1.5 Tesla MRI. Cancer Research 2003; 63:5838-43.

CVD MRI
Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Robertson JD, Lanza GM, Wickline SA: Molecular imaging of angiogenesis in early-stage atherosclerosis with avb3-integrin-targeted nanoparticles. Circulation 2003; 108:2270-4.

CVD MRI
Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA, Lanza GM: Novel MRI contrast agent for molecular imaging of fibrin: Implications for detecting vulnerable plaques. Circulation 2001; 104: 1280-1285.


CVD Targeted Therapy

Lanza GM, Yu X, Winter PM, Abendschein DR, Karukstis KK, Scott MJ, Chinen, LK, Fuhrhop RW, Scherrer DE, Wickline SA: Targeted antiproliferative drug delivery to vascular smooth muscle cells with magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 2002; 106:2842-2847.

Ultrasound Molecular Imaging
Lanza GM, Wallace KD, Scott MJ, Cacheris WP, Abendschein DR, Christy DH, Sharkey AM, Miller JG, Gaffney PJ, Wickline SA: A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation 1996; 94: 3334-3340.